Pacific Edge Limited (NZX/ASX: PEB) has welcomed a decision from Novitas and First Coast to delay the implementation of the Local Coverage Determination (LCD, L35396) that would have seen Medicare coverage of Cxbladder cease in the US on 17 July 2023.
The decision was made following a discussion between Pacific Edge and Novitas regarding the substance of their evidentiary review of Cxbladder products.
Pacific Edge Chief Executive Dr Meintjes stated that the company supports efforts to ensure the Medicare program only pays for genetic testing services that are analytically valid, clinically valid, and clinically useful.
No time frame has been provided for the process.
See more
